SCORE

51

NEOS: Neos Therapeutics is a Buy


The current rating for NEOS is 51, which is 2% above its historic median rating of 50. This indicates lower risk than normal.


The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.